Enhancement of bleomycin-induced micronucleus formation in V79 cells as a rapid and sensitive screen for non-covalent DNA-binding compounds

• Published in: Mutation research Vol. 444; no. 1; pp. 181 - 192
• Main Authors: Snyder, Ronald D, Strekowski, Lucjan
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 21.07.1999; Elsevier
• Subjects: Animals; Biological and medical sciences; Bleomycin; Bleomycin - chemistry; Bleomycin - toxicity; Cell Line; Cricetinae; DNA - drug effects; DNA - metabolism; DNA intercalation; Drug Evaluation, Preclinical; Drug toxicity and drugs side effects treatment; Intercalating Agents - chemistry; Intercalating Agents - toxicity; Medical sciences; Micronucleus; Micronucleus Tests - methods; Miscellaneous (drug allergy, mutagens, teratogens...); Mutagens - chemistry; Mutagens - toxicity; Pharmacology. Drug treatments; Structure-Activity Relationship; DNA intercalation; Bleomycin; Micronucleus; Antineoplastic agent; Chromosomal aberration; Intercalating agent; Mutagenicity testing; Toxicity; Rodentia; Method; Vertebrata; Mammalia; Cell line; DNA; Detection; Hamster
• ISSN: 1383-5718; 0027-5107; 1879-3592
• DOI: 10.1016/S1383-5718(99)00080-7

Non-covalent drug/DNA interactions are difficult to study and because of this, the significance of such interactions from a safety standpoint and their contribution to positive genetic toxicology test findings is poorly understood. It is shown in the present study that such interactions may be detected and quantified in Chinese hamster V79 cells by an adaptation of the bleomycin amplification assay. This assay measures the ability of a test compound to enhance the DNA damaging activity of the antibiotic bleomycin using micronucleus formation as an endpoint. Results are presented examining the bleomycin amplification activity of known intercalating agents, groove-binding agents and other structurally diverse classes of compounds for which intercalative status has not been reported. The assay reveals a strong and predictable SAR for amplification activity based on number and orientation of aromatic rings. Moreover, excellent correlations are observed between DNA binding (viscometric analyses) and DNA amplification in V79 cells for a series of seven experimental compounds. The assay is shown to be useful in understanding the genotoxicity of marketed antihistamines and to help explain genetic toxicology findings observed in a series of novel pharmaceutical entities. It is proposed that assessment of bleomycin amplification activity of novel compounds in early genotoxicity prescreening may provide important information upon which to base synthesis of compounds with minimal or no genotoxic liability.